Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-101 IV in healthy volunteers
NCT03500627Phase 1Completed
- Sponsor
- Orpheris, Inc.
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of N-acetyl cysteine dendrimer conjugate in cerebral adrenoleukodystrophy (CALD) (3 cohorts), sponsored by Orpheris, Inc. Primary endpoint: Treatment Emergent Adverse Events at Day 15. Started Mar 2018; status: completed.
02
Drugs
N-acetyl cysteine dendrimer conjugate
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NCT03500627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500627.